# Neuro-Ophthalmic Presentation of Steroid 5a-Reductase Type 3 Congenital Disorder of Glycosylation: A Case of Monozygotic Twins

**Authors:** Shikha Swaroop, Sudeshna Dasgupta, Preeti Srivastava, Shikhar Deep Jain, Deb Sanjay Nag, Sanjay K Tanti

PMC · DOI: 10.7759/cureus.102557 · Cureus · 2026-01-29

## TL;DR

This paper describes a rare genetic disorder in twin sisters, highlighting unique neurological and ocular symptoms caused by a mutation in the SRD5A3 gene.

## Contribution

The study reports a novel case of SRD5A3-CDG in monozygotic twins with early seizures and optic atrophy, despite normal brain imaging.

## Key findings

- The twins exhibited generalized seizures and optic atrophy, features not commonly reported in SRD5A3-CDG.
- Brain MRIs were normal despite severe neurological symptoms, indicating phenotypic diversity in SRD5A3-CDG.
- A homozygous nonsense mutation in the SRD5A3 gene was identified as the cause of the disorder.

## Abstract

We report a very rare autosomal recessive metabolic disorder in monozygotic twin sisters caused by the steroid 5a-reductase type 3 (SRD5A3) gene defect, a subtype of congenital disorder of glycosylation (CDG). SRD5A3 activity is required for N-glycosylation of proteins. This step is important for the protein to gain its function. The condition is characterized by severe neurodevelopmental delay, cerebellar atrophy or hypoplasia, ocular abnormalities, and ichthyotic skin changes. We describe 20-month-old female monozygotic twins born to non-consanguineous South Asian parents. Notably, both twins exhibited generalized tonic-clonic seizures starting in early infancy - a feature less commonly reported in SRD5A3-CDG. Physical examination of both children showed central hypotonia and bilateral horizontal nystagmus. Fundoscopy of the twins showed optic disc pallor suggestive of optic atrophy. Other features, such as ichthyosis and joint laxity, were absent. Crucially, despite prominent neurological symptoms, brain MRIs at 20 months were entirely normal, showing no evidence of cerebellar hypoplasia or atrophy typically associated with this condition. Whole-exome sequencing identified a homozygous nonsense mutation at exon 1 c.57G>A (p.Trp19Ter), in the SRD5A3 gene, classified as a pathogenic variant as per the American College of Medical Genetics and Genomics (ACMG), helping in establishing the diagnosis. SRD5A3-CDG should be one of the differentials in infants with unexplained seizures, hypotonia, and early ocular signs. This case highlights the phenotypic diversity of SRD5A3-CDG and demonstrates that structural brain anomalies may be absent in the early years of life. It underscores the importance of considering CDG as a differential in infants with unexplained hypotonia and ocular signs, even in the setting of normal neuroimaging.

## Linked entities

- **Genes:** SRD5A3 (steroid 5 alpha-reductase 3) [NCBI Gene 79644]
- **Diseases:** congenital disorder of glycosylation (MONDO:0015286), SRD5A3-CDG (MONDO:0012885)

## Full-text entities

- **Genes:** TF (transferrin) [NCBI Gene 7018] {aka HEL-S-71p, PRO1557, PRO2086, TFQTL1}, SRD5A3 (steroid 5 alpha-reductase 3) [NCBI Gene 79644] {aka CDG1P, CDG1Q, KRIZI, S5AR, S5AR 3, SRD5A2L}, PPP5C (protein phosphatase 5 catalytic subunit) [NCBI Gene 5536] {aka PP5, PPP5, PPT}, ALPP (alkaline phosphatase, placental) [NCBI Gene 250] {aka ALP, PALP, PLAP, PLAP-1}
- **Diseases:** brain abnormalities (MESH:D001927), Mitochondrial encephalopathy (MESH:C538525), inherited metabolic disorders (MESH:D020739), LCA (MESH:D057130), tonic-clonic (MESH:D004830), central hypotonia (MESH:D009123), brainstem abnormalities (MESH:D020295), neurodevelopmental delay (MESH:D006968), infection (MESH:D007239), ichthyotic skin changes (MESH:C536560), cardiac anomalies (MESH:D006331), joint laxity (MESH:D007593), neurodevelopmental impairment (MESH:D009422), ichthyosis (MESH:D007057), developmental delay (MESH:D002658), optic atrophy (MESH:D009896), hypoplasia (MESH:D000080344), anomaly (MESH:D000013), optic disc (MESH:D009901), atrophy (MESH:D001284), atrophic changes in the brain (MESH:D020966), ocular abnormalities (MESH:D005124), horizontal nystagmus (MESH:D009759), Joubert syndrome (MESH:C536293), CDG (MESH:D018981), cutaneous abnormalities (MESH:D018366), Facial dysmorphism (MESH:C565579), cerebellar atrophy or hypoplasia (MESH:C562568), neurological and ocular deficits (MESH:D009461), autosomal recessive metabolic disorder (MESH:D008659), Seizures (MESH:D012640), coloboma (MESH:D003103), cerebellar atrophy (MESH:D002526)
- **Chemicals:** polyprenol (MESH:D000081026), N-linked glycosylation (-), sodium valproate (MESH:D014635), lipid (MESH:D008055), vitamin D (MESH:D014807), glycans (MESH:D011134), dolichol (MESH:D004286)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** p.Trp19Ter

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12949591/full.md

## References

13 references — full list in the complete paper: https://tomesphere.com/paper/PMC12949591/full.md

---
Source: https://tomesphere.com/paper/PMC12949591